Evidence map›Paper›PMID 42274778›Full record

ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2026

[Doping in chess].

Thomas E Wessendorf

Abstract readEnglish AbstractReview
In one paragraph

Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Thomas E WessendorfRuhrlandklinik, Universitätsmedizin Essen, Universität Duisburg-Essen, Tüschener Weg 40, 45239, Essen, Deutschland. thomas.wessendorf@rlk.uk-essen.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of performance-enhancing substances is also possible in chess. Regarding stimulants used for cognitive doping-such as amphetamines, methylphenidate, modafinil, and ephedrine-there is evidence suggesting a slight improvement in performance; however, there is also evidence of negative effects on decision-making processes under time pressure. These substances generally pose a health risk; particularly in cases of overdose, they can strain the cardiovascular system or trigger psychotic symptoms. Furthermore, there is a fundamental risk of addiction or of the substance serving as a "gateway drug."As chess is recognized as an official sport, doping controls are conducted within organized competitions. However, these are limited to elite-level competition and are consequently rare; as a result, few significant doping cases have come to light thus far. In contrast, a higher prevalence is suspected in competitive and amateur chess-among both professionals and amateurs alike. Nevertheless, the greater threat to fair play in chess lies in other fraudulent methods (such as cheating or electronic doping).

Indexed as

Central Nervous System StimulantsDoping in SportsPerformance-Enhancing SubstancesSubstance Abuse DetectionGermanyHumansCentral Nervous System StimulantsPerformance-Enhancing SubstancesCheatingChessDopingNeuro enhancementStimulants

Identifiers

PMID42274778
PMCPMC13323405

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.